SEVEN PLUS CONTINOUS GLUCOSE MONITORING SYSTEM

FDA Premarket Approval P050012 S001

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the sts-7 continuous glucose monitoring system (sts-7 system). The device is indicated for the following: the sts-7 continuous glucose monitoring system (sts-7 system) is a glucose-monitoring device indicated for detecting trends and tracking patterns in adults (age 18 and older) with diabetes. The sts-7 system is intended for use by patients at home and in health care facilities. The device is for prescription use only. The sts-7 continuous glucose monitoring system is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home glucose monitoring devices. The sts-7 continuous glucose monitoring system aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimize these excursions. Interpretation of the sts-7 system results should be based on the trends and patterns seen with several sequential readings over time.

DeviceSEVEN PLUS CONTINOUS GLUCOSE MONITORING SYSTEM
Generic NameSensor, Glucose, Invasive
ApplicantDEXCOM, INC.
Date Received2006-06-19
Decision Date2007-05-31
Notice Date2007-06-28
PMAP050012
SupplementS001
Product CodeMDS 
Docket Number07M-0255
Advisory CommitteeClinical Chemistry
Supplement TypePanel Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address DEXCOM, INC. 5555 Oberlin Dr san Diego, CA 92121
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P050012Original Filing
S052 2013-12-06 Real-time Process
S051 2013-07-26 30-day Notice
S050 2012-09-25 135 Review Track For 30-day Notice
S049 2012-09-24 30-day Notice
S048 2012-07-05 30-day Notice
S047 2012-05-30 30-day Notice
S046 2012-03-16 135 Review Track For 30-day Notice
S045 2012-02-21 Normal 180 Day Track
S044 2012-01-03 Real-time Process
S043 2011-12-21 30-day Notice
S042 2011-10-17 135 Review Track For 30-day Notice
S041 2011-08-15 135 Review Track For 30-day Notice
S040
S039 2011-08-15 135 Review Track For 30-day Notice
S038 2011-07-14 30-day Notice
S037 2011-04-08 Real-time Process
S036 2011-01-31 30-day Notice
S035 2010-12-08 135 Review Track For 30-day Notice
S034 2010-11-12 30-day Notice
S033 2010-11-12 135 Review Track For 30-day Notice
S032 2010-08-04 30-day Notice
S031 2010-07-30 Real-time Process
S030 2010-07-30 Real-time Process
S029 2010-07-30 30-day Notice
S028 2010-07-28 30-day Notice
S027 2010-07-13 Real-time Process
S026
S025 2010-06-15 Special (immediate Track)
S024 2010-05-12 30-day Notice
S023
S022 2009-12-30 30-day Notice
S021 2009-11-05 30-day Notice
S020 2009-08-26 30-day Notice
S019 2009-08-20 30-day Notice
S018 2009-03-09 Real-time Process
S017 2008-09-23 Normal 180 Day Track
S016 2008-08-04 Normal 180 Day Track
S015 2008-06-19 30-day Notice
S014 2008-04-01 Real-time Process
S013 2007-12-13 30-day Notice
S012 2007-08-20 Normal 180 Day Track No User Fee
S011 2007-06-05 Normal 180 Day Track
S010 2007-04-16 Real-time Process
S009 2007-03-26 30-day Notice
S008 2007-03-01 30-day Notice
S007 2007-02-06 30-day Notice
S006 2007-01-03 30-day Notice
S005 2006-12-06 30-day Notice
S004 2006-09-07 30-day Notice
S003 2006-08-21 30-day Notice
S002 2006-07-28 Real-time Process
S001 2006-06-19 Panel Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.